Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06317285 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 4, 2024
- Completion date
- October 1, 2025
- Enrollment
- 158 (actual)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.